Scientific priorities and real prospects for cost optimization in formulation development

Galina T. Glembotskaya (), Stanislav Yu. Eremin () and Elena E. Chupandina
Additional contact information
Galina T. Glembotskaya: I.M. Sechenov First Moscow State Medical University, Russian Federation
Stanislav Yu. Eremin: I.M. Sechenov First Moscow State Medical University, Russian Federation
Elena E. Chupandina: Voronezh State University, Russian Federation

Entrepreneurship and Sustainability Issues, 2020, vol. 7, issue 3, 1484-1499

Abstract: As a result of the systematic structural analysis of the collected scientific data on the problem under study, the trends in the development of the pharmaceutical sector that have established in the global space, including the Russian Federation, have been marked, the changes in the modern healthcare systems have been noted, and it has been proven that the problem of finding accelerated and efficient methods of drug development that meet the interests of all stakeholders needs the priority solution. The structure of distributing the clinical studies of drugs in the world practice has been presented, and data on the funds for the development of the main stages of the process under study and therapeutic groups of drugs for various nosologies have been presented. The main difficulties of objective assessment of the formulation development costs have been defined, the influencing factors have been identified, and the methodical approach to calculating the resources spent has been proposed. The results have been summarized, and the prospects for the rational use of the advanced information technologies for the development and support of innovative domestic developments in the pharmaceutical sector have been demonstrated. As a result of the research into the scientific data, a real opportunity to optimize the costs of developing innovative drugs through their repositioning has been demonstrated for the first time, the conceptual methodical approach to solving the identified problems has been justified, and prospects for its implementation have been outlined, with due consideration for the further development of the pharmaceutical market and the introduction of personalized pharmaceutical care. The study has been conducted on the basis of systematic analytical structuring of the information data and the results of independent research with the identification of global trends and the determination of practical significance, as well as scientific perspectives in the field under study.

Keywords: drug development; stages of development; efficiency of phases of clinical studies; capabilities of Artificial Intelligence in the development; cost optimization; repositioning of drugs (search for similar items in EconPapers)
JEL-codes: O31 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://jssidoi.org/jesi/uploads/articles/27/Glemb ... tion_development.pdf (application/pdf)
https://jssidoi.org/jesi/article/470 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ssi:jouesi:v:7:y:2020:i:3:p:1484-1499

DOI: 10.9770/jesi.2020.7.3(4)

Access Statistics for this article

Entrepreneurship and Sustainability Issues is currently edited by Manuela Tvaronaviciene

More articles in Entrepreneurship and Sustainability Issues from VsI Entrepreneurship and Sustainability Center
Bibliographic data for series maintained by Manuela Tvaronaviciene ().